Turkish Parkinson's Disease Dyskinesia Scale (PDYS-26): checking reliability and validity
Official title: Adaptation Of The Parkinson's Disease Dyskinesia Questionnaire Into Turkish And Its Validity And Reliability In Parkinson's Patient
Run by Izmir Bakircay University · NCT07023224 · Data updated 2026-11-12
This project tests whether the Turkish PDYS-26 reliably measures dyskinesia and its impact on daily life in people with idiopathic Parkinson's disease (H&Y stages 1–3) who have at least mild dyskinesia.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 130 (estimated) |
| Sponsor | Izmir Bakircay University Academic / other |
| Locations | 2 sites (Izmir, İ̇zmi̇r and 1 other locations) |
| Status | Recruiting |
| Started | November 14, 2024 |
| Main results expected | November 30, 2025 |
| Study ends | December 1, 2025 |
| Registry record updated | September 19, 2025 |
| Trial ID | NCT07023224 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are Turkish-speaking adults with idiopathic Parkinson's disease (H&Y stages 1–3), UPDRS dyskinesia item score ≥1, MMSE ≥24, and willingness to attend local study visits.
✕Probably not a fit
Patients with atypical or secondary parkinsonism, severe musculoskeletal/neurological/cardiopulmonary conditions, significant cognitive impairment (MMSE <24), no dyskinesia, or who cannot attend visits in İzmir are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational methodological project translates the PDYS-26 into Turkish using back-translation and expert committee review, then applies the final scale to 130 people with idiopathic Parkinson's disease. Participants will be H&Y stages 1–3 with at least mild dyskinesia (UPDRS dyskinesia item ≥1) and MMSE ≥24, with atypical parkinsonism and major comorbidities excluded. Validity will be tested by comparing PDYS-26 scores with the Tampa Kinesiophobia Scale, Mini-BESTest, Activity-specific Balance Confidence (ABC) scale, and Parkinson's Disease Questionnaire-39, and reliability will be examined via internal consistency and test-retest methods. All visits occur at Bakırçay University sites in İzmir and no drug treatments are administered as part of the project.
Why it matters
Potential benefit: If successful, clinicians and researchers in Turkey will have a validated Turkish PDYS-26 to better measure dyskinesia severity and its effect on daily activities, supporting improved treatment and rehabilitation decisions.
How similar studies have gone: Validation studies of dyskinesia and Parkinson's scales in other languages have generally shown reliable and valid results, but this is the first reported validation of the PDYS-26 in Turkish.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Being diagnosed with idiopathic Parkinson's disease * H\&Y stage 1-3 * UPDRS dyskinesia item score ≥1 * Accepting to participate in the study Exclusion Criteria: * Diagnosis of atypical-secondary parkinsonism * Severe musculoskeletal, neurological and/or cardiopulmonary problems that may affect the results of the assessment * Mini Mental State Examination score \< 24
Where it's running
-
Bakirçay University Çiğli Regional Education Hospital
Izmir, İ̇zmi̇r, Turkey (Türkiye) Recruiting -
Izmir Bakırçay Univercity
Izmir, Turkey (Türkiye) Recruiting
Study contacts
- Principal investigator: Gulbın Ergın, PT, PhD — Izmir Bakircay Univercity
- Study coordinator: Irem Tepe Bark, PT
- Email: fztiremtepe@gmail.com
- Phone: +905537491143
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Registry and natural history of epilepsy-dyskinesia syndromes
This registry will collect health data and biological samples from people of all ages who have a genetic diagnosis of epilepsy-dyskinesia syndromes to see how their genes relate to their movement and seizure symptoms over time.
-
Investigating NEU-411 for Early Parkinson's Disease
This study is testing a new drug called NEU-411 to see if it can help people aged 50-80 with early Parkinson's Disease who have a specific genetic marker.
-
Understanding epilepsy-dyskinesia syndromes in children
This study is trying to learn more about epilepsy-dyskinesia syndromes in children by gathering information from different countries to see how these movement and seizure disorders are related.
-
Validation of a deep learning platform for diagnosing isolated dystonia
This study is testing a new deep learning tool to see if it can help doctors diagnose isolated dystonia more accurately and quickly.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.